This document provides guidance for the clinical evaluation of drugs in the prevention of cardiovascular events.

Keywords: Cardiovascular prevention, risk scoring models, SCORE system, Framingham risk score

Current effective version

Guideline on the evaluation of medicinal products for cardiovascular disease prevention

AdoptedLegal effective date: Reference Number: EMEA/CHMP/EWP/311890/2007

English (EN) (112.36 KB - PDF)

First published: Last updated:
View

Document history

Overview of comments received on draft guideline on the evaluation of medicinal products for cardiovascular disease prevention (EMEA/CHMP/EWP/311890/2007)

Reference Number: EMEA/CHMP/EWP/357298/2008

English (EN) (105.13 KB - PDF)

First published: Last updated:
View

Draft guideline on the evaluation of medicinal products for cardiovascular disease prevention

Draft: consultation closedReference Number: EMEA/CHMP/EWP/311890/2007

English (EN) (50.29 KB - PDF)

First published: Last updated:
View

Concept paper on the development of a committee for medicinal products for human use (CHMP) note for guidance on the need for regulatory guidance in the evaluation of medicinal products for the secondary cardiovascular p...

Reference Number: CHMP/EWP/1470/04

English (EN) (134.84 KB - PDF)

First published: Last updated:
View

Share this page